November 22, 2016 - By Linda Rogers · 0 Comments
The stock of Zogenix Incorporated (NASDAQ:ZGNX) registered an increase of 2.97% in short interest. ZGNX’s total short interest was 3.56 million shares in November as published by FINRA. Its up 2.97% from 3.46M shares, reported previously. With 133,100 shares average volume, it will take short sellers 27 days to cover their ZGNX’s short positions. The short interest to Zogenix Incorporated’s float is 18.12%. The stock closed at $12.85 during the last session. It is down 17.78% since April 20, 2016 and is uptrending. It has outperformed by 13.23% the S&P500.
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The company has a market cap of $338.31 million. The Company’s areas of focus are epilepsy and schizophrenia. It currently has negative earnings. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine.
Out of 3 analysts covering Zogenix (NASDAQ:ZGNX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zogenix has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, August 11 by Leerink Swann. The rating was upgraded by Zacks to “Sell” on Thursday, August 6. The rating was upgraded by Zacks to “Hold” on Saturday, August 15. Brean Capital maintained it with “Buy” rating and $28 target price in Thursday, September 17 report. The firm earned “Buy” rating on Friday, August 14 by Brean Capital.
Zogenix, Inc., incorporated on May 11, 2006, is a pharmaceutical firm engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine. The Firm is also engaged in the development of Relday. It is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, under an Asset Purchase Agreement with Endo Ventures Bermuda Limited and Endo Ventures Limited (collectively, Endo). The Firm sells Sumavel DosePro to Endo.
More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Fool.com which released: “Zogenix, Inc. Shares Galloped 15% Higher in February — Here’s Why” on March 10, 2016, also Fool.com with their article: “Zogenix, Inc Gained 29% in 2015 — Here’s Why” published on January 14, 2016, Fool.com published: “Why Zogenix, Inc. Shares Were Throttled” on April 27, 2015. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: Fool.com and their article: “Why Zogenix, Inc. Shares Rocketed 22% Higher in May” published on June 05, 2015 as well as Fool.com‘s news article titled: “Zogenix Inc. Shares Crumbled in March — Here’s Why” with publication date: April 10, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers